팝업레이어 알림

PREV

NEXT

AAV Capsid Engineering

CARE™ explores novel AAV vectors with improved on-target specificity offering clinical safety.

AAV Gene Therapies
to Cure CNS Genetic Disorders

For patients and clinicians fighting for rare genetic diseases

Non-GMP CDMO Services

We design and serve plasmids, vectors,
and viruses for AAV
gene therapy programs from researchers
to bio-pharmas around the world.

Business

CARE™, Cell-specific AAV Research Engine

Meet the demands of organization-specific AAV capsid with CARE™

Business

AAV gene therapy programs

Genixcure develops therapeutic programs for CNS & genetic rare diseases

Business

Non-GMP grade CMO

PIPELINE

Candidate Indication Development status
  • Research
  • Lead Optimization
  • In Vitro
  • In Vivo
  • Phase Ⅰ
  • Phase Ⅱ
  • Phase Ⅲ
  • NDA
  • Commercialization
Neuro-Degenerative Disorder GXC-101
In Vivo

Rare Genetic Disease GXC-301 Lafora disease
In Vivo
ODD & RPDD granted by US FDA

GXC-302 Undisclosed
In Vitro

GXC-303 ALS
In Vitro

GXC-304 Fronto Temporal Dementia
In Vivo

좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.

PARTNER

  • Partner
  • Investment
  • Modalis Therapeutics

  • Charles River

  • Premier Research

  • Temple University Lewis Katz School of Medicine

  • Biovian

  • HYUNDAI VENTURE INVESTMENT

  • POSCO CAPITAL

  • KyungDong pharm

  • Friend Investment Partners

  • BNK VENTURE CAPITAL

NOTICE

VIEW MORE

NEWS

VIEW MORE

TOP